NCT07840443
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07840443
Title Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma (CARA)
Acronym CARA
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors University Health Network, Toronto
Indications
Therapies
Age Groups: senior | adult
Covered Countries CAN